Cascadian Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch CASC and buy or sell other stocks, ETFs, and their options commission-free!

About CASC

Cascadian Therapeutics LLC was a clinical-stage biopharmaceutical company, which focused on the development of therapeutic products for the treatment of cancer. Its product ONT-380, was an orally active and selective small-molecule HER2 inhibitor. 

CEO
Scott D. Myers, MBA
CEOScott D. Myers, MBA
Employees
Employees
Headquarters
Bothell, Washington
HeadquartersBothell, Washington
Founded
2007
Founded2007
Employees
Employees

CASC Key Statistics

Market cap
507.00M
Market cap507.00M
Price-Earnings ratio
-8.28
Price-Earnings ratio-8.28
Dividend yield
Dividend yield
Average volume
339.82K
Average volume339.82K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$10.21
52 Week high$10.21
52 Week low
$3.18
52 Week low$3.18

Stock Snapshot

Cascadian Therapeutics(CASC) stock is priced at $10.02, giving the company a market capitalization of 507M. It carries a P/E multiple of -8.28.

On 2026-03-03, Cascadian Therapeutics(CASC) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for Cascadian Therapeutics(CASC) stock has reached 0, versus its average volume of 339.82K.

The stock's 52-week range extends from a low of $3.18 to a high of $10.21.

The stock's 52-week range extends from a low of $3.18 to a high of $10.21.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.